Epizyme (EPZM) : During the past 4 weeks, traders have been relatively bearish on Epizyme (EPZM), hence the stock is down -15.95% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -19.33% relative to the S&P 500. The 4-week change in the price of the stock is -15.09% and the stock has fallen -19.28% in the past 1 week.
The stock has recorded a 20-day Moving Average of 15.19% and the 50-Day Moving Average is 20.82%. Epizyme (NASDAQ:EPZM): stock turned positive on Friday. Though the stock opened at $8.22, the bulls momentum made the stock top out at $8.48 level for the day. The stock recorded a low of $8.16 and closed the trading day at $8.33, in the green by 0.60%. The total traded volume for the day was 506,624. The stock had closed at $8.28 in the previous days trading.
The company Insiders own 25.4% of Epizyme shares according to the proxy statements. Institutional Investors own 81.66% of Epizyme shares. During last six month period, the net percent change held by insiders has seen a change of 13.47%.
Epizyme, Inc. is a clinical-stage biopharmaceutical company that discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Companys product platform creates small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. The Companys lead product candidate, EPZ-6438 is an inhibitor that targets the EZH2 HMT. The Company is conducting a Phase I/II clinical trial of EPZ-6438 in patients with relapsed or refractory B-cell lymphoma or advanced solid tumors. Its product pipeline includes EPZ-6438 (EZH2 inhibitor) and EPZ-5676 (DOT1L inhibitor). It has commercial rights for EPZ-6438 (EZH2 inhibitor) under the name Epizyme across the world excluding Japan and as Eisai in Japan. EPZ-5676 (DOT1L inhibitor) is in Phase I MLL-r adult patient trial ongoing for dose escalation fully enrolled in MLL-r adult patient trial and MLL-r only adult expansion enrolling, and Phase I MLL-r pediatric patient trial enrolling.